# Immunome

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunome

- Industry: Biotechnology
- Headquarters: Bothell, US
- Website: www.immunome.com
- Total disclosed funding: $11M
- Latest round: Series A (Jun 2, 2020)
- Investors on record: 1

## About

Based in Washington, US, and founded in 2008 by CSO Scott Dessain, Immunome Inc., a.k.a. Immunome operates as a biotechnology company that develops novel antibody-based therapeutics by unlocking the human memory B cell response. In February 2024, Immunome Inc. raised USD 200 million in a private placement, selling 10 million shares at USD 20 per share on the NASDAQ under the ticker symbol IMNM.

Immunome focuses on developing targeted therapies for oncology. The company’s work includes creating advanced treatments that specifically target cancer cells. Immunome’s approach involves leveraging cutting-edge technology and scientific research to develop these specialized therapies.

## Funding rounds

- Series A, Jun 2, 2020, $11M — Robin Hood Ventures
- Series A, May 12, 2020, $0.2M — Robin Hood Ventures
- Series A, Dec 3, 2019, $0.2M — Robin Hood Ventures

## Investors

- Robin Hood Ventures (https://capitalatlas.ai/funds/robin-hood-ventures) — Series A